<div id="readability-page-1"><div> <div> Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer , /PRNewswire/ -- (TSXV: PAIN) — Vector Science &amp; Therapeutics (the &#34;Company&#34;) today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the unmet need remains significant. Pancreatic cancer represents one of oncology's most studied and persistent unmet needs. Approximately 80% of patients are diagnosed at a locally advanced or metastatic stage (National Cancer Institute/NCI), where surgery is not feasible. Despite available systemic regimens, five-year survival rates remain below 5% for this population (NCI), and the literature reflects sustained scientific interest in localized delivery strategies as a complement to or alternative to systemic approaches. Vector's provisional patent describes a platform architecture intended to advance that area of research. The platform integrates three research modalities: intratumoral delivery of cell differentiation agents, electrical ablation based on the differential conductivity of tumor tissue, and electrically-guided chemotherapy activation. &#34;Each of the three modalities in this platform has a basis in the existing literature. The integration is novel. Our work now is to build the preclinical evidence that will determine whether that integration delivers what the science suggests is possible.&#34; — Tom Bachinski, Chief Technology Officer, Vector Science &amp; Therapeutics The provisional patent filing establishes and protects the intellectual property position as preclinical work begins. The Company's immediate focus is on proof-of-principle validation: generating the foundational data required to assess feasibility, refine the system architecture, and support future regulatory and clinical collaboration. No preclinical or clinical data have yet been generated or published for this specific platform. ABOUT VECTOR SCIENCE &amp; THERAPEUTICS Vector Science &amp; Therapeutics, Inc., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the Company's immediate focus on the product, and the potential of the described technology. These statements involve known and unknown risks and uncertainties. The provisional patent application has been filed but has not been granted. No assurance can be given that clinical or regulatory milestones will be achieved on any particular timeline, or at all. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including expectations and assumptions concerning the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by the management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The information in this release is provided as of the date hereof and Vector Science &amp; Therapeutics undertakes no obligation to update forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release SOURCE Vector Sciences &amp; Therapeutics <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz"/></div> </div></div>

VTVT

SBIO

LABU

Vector Science & Therapeutics has filed a provisional patent for a novel microneedle catheter platform aimed at intratumoral drug delivery, focusing initially on pancreatic cancer. The platform integrates three modalities: intratumoral delivery of cell differentiation agents, electrical ablation, and electrically-guided chemotherapy activation. This filing marks the start of a preclinical research program to validate the technology's feasibility and support future regulatory collaborations. The company aims to generate foundational data to refine the system architecture, although no preclinical or clinical data have been published yet.

prnewswire

vTv Therap

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

09:26 ETVector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery